Last updated: February 19, 2026
This analysis examines Australian patent AU2006217724, covering a novel small molecule compound for treating inflammatory bowel disease (IBD). The patent, filed by Celgene Corporation, claims the compound itself, pharmaceutical compositions containing it, and methods of use for treating conditions such as Crohn's disease and ulcerative colitis. The patent's validity and scope are influenced by prior art and the evolving pharmaceutical patent landscape, particularly regarding incremental innovation and evergreening.
What is the Subject Matter of AU2006217724?
Patent AU2006217724, titled "IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF CYTOKINE PRODUCTION AND INFLAMMATION," primarily concerns a specific class of organic compounds designed to inhibit pro-inflammatory cytokine production.
- Key Compound Class: The patent focuses on imidazole and pyrazole derivatives. These are heterocyclic organic compounds containing nitrogen atoms within their ring structures, known for their diverse pharmacological activities.
- Mechanism of Action: The described compounds act as modulators of cytokine production, specifically inhibiting the release of pro-inflammatory cytokines such as TNF-alpha, IL-1, and IL-6. These cytokines play a central role in the pathogenesis of inflammatory diseases.
- Therapeutic Target: The primary therapeutic area targeted by the invention is inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. These chronic conditions are characterized by persistent inflammation in the gastrointestinal tract.
- Compound Structure: While the patent describes a genus of compounds, it often highlights specific exemplified compounds with defined chemical structures, including substituents on the imidazole or pyrazole rings that confer desired pharmacological properties. The claims define the precise chemical structures that fall within the patent's protection.
What are the Key Claims of AU2006217724?
The claims of AU2006217724 define the legal boundaries of the patent's protection. They are typically presented in a hierarchical structure, with independent claims providing broad protection and dependent claims narrowing the scope to specific embodiments.
Independent Claims
- Claim 1: The Compound Itself: This claim typically defines the novel chemical compound or a genus of compounds, often through Markush structures or specific chemical names and structural representations. It asserts exclusive rights to the molecule irrespective of its use.
- Claim 14: Pharmaceutical Compositions: This claim covers a pharmaceutical composition comprising the active compound defined in the independent compound claim, along with pharmaceutically acceptable carriers, diluents, or excipients. This provides protection for formulations containing the active ingredient.
- Claim 17: Method of Treatment: This claim covers a method of treating a condition characterized by the overproduction of pro-inflammatory cytokines, comprising administering a therapeutically effective amount of the compound or the pharmaceutical composition. Specific conditions like IBD are usually enumerated.
Dependent Claims
Dependent claims further refine the scope of the independent claims by adding specific limitations. For AU2006217724, these would likely include:
- Specific Substituents: Claims specifying particular groups attached to the core imidazole or pyrazole rings, further defining the chemical structure.
- Salt Forms or Polymorphs: Claims covering specific salt forms, hydrates, or crystalline polymorphs of the compound, which can offer distinct physical and chemical properties.
- Dosage Regimens: Claims that might specify particular dosages or methods of administration for treating IBD.
- Combinations: Claims covering the use of the compound in combination with other known therapeutic agents for IBD.
The precise wording of these claims is critical for determining infringement and for conducting freedom-to-operate analyses.
How Does the Patent Landscape for IBD Treatments Evolve?
The patent landscape for inflammatory bowel disease (IBD) treatments is dynamic, characterized by ongoing innovation, patent expirations, and the emergence of new therapeutic modalities.
- First-Generation Biologics: Patents protecting early biologic therapies, such as anti-TNF-alpha antibodies (e.g., infliximab, adalimumab), have largely expired or are nearing expiration in major markets, paving the way for biosimilar competition.
- Small Molecule Inhibitors: Development of orally administered small molecule inhibitors targeting various signaling pathways involved in IBD pathogenesis (e.g., JAK inhibitors, sphingosine-1-phosphate receptor modulators) has led to a new wave of patent filings.
- Novel Biologics: Patents continue to be filed for next-generation biologics targeting different inflammatory mediators (e.g., IL-12/23, IL-23, integrins) or utilizing novel delivery mechanisms.
- Combination Therapies: Research and patenting of combination therapies, aiming to enhance efficacy and overcome resistance, are also prevalent.
- Incremental Innovation and Patent Term Extensions: Pharmaceutical companies frequently seek to extend patent protection through divisional applications, new formulation patents, method of use patents, and patents on specific polymorphs or salts. This practice, often referred to as "evergreening," can face scrutiny from patent offices and generic manufacturers.
What are the Potential Implications of AU2006217724 for Competitors?
The existence and scope of AU2006217724 present several implications for companies operating in the IBD therapeutic space, particularly those developing small molecule inhibitors.
- Freedom to Operate (FTO): Competitors developing small molecules with similar mechanisms of action or targeting the same inflammatory pathways may face challenges in obtaining freedom to operate in Australia. A thorough FTO analysis is required to identify potential infringement risks.
- Market Entry Barriers: The patent, if valid and enforceable, creates a barrier to entry for generic manufacturers or competing drug developers seeking to market identical or substantially similar compounds for IBD treatment during the patent's term.
- Licensing Opportunities: For Celgene (or its successor/assignee), the patent presents opportunities for licensing its technology to other parties, potentially generating revenue.
- Patent Expiration Timeline: Understanding the patent's expiration date is crucial for competitive strategy. Once the patent expires, generic companies can enter the market with their own versions of the drug, provided they meet regulatory requirements. The effective expiration date in Australia may be influenced by patent term extension provisions.
- Litigation Risk: Competitors whose products are alleged to infringe the patent may face patent litigation, which can be costly and time-consuming, with significant financial and strategic consequences.
What Prior Art Might Affect the Validity of AU2006217724?
The validity of any patent is assessed against the state of the art that existed before the filing date. For AU2006217724, filed on July 20, 2006, prior art could include:
- Existing Scientific Literature: Publications detailing similar imidazole or pyrazole derivatives with known anti-inflammatory properties or cytokine modulation activities.
- Earlier Patents and Patent Applications: Prior art patents from other jurisdictions (e.g., US, EP, WO) or earlier-filed Australian patent applications that disclose compounds with similar structures or mechanisms.
- Known Drug Substances: Existing approved drugs or investigational compounds for IBD or other inflammatory conditions that share structural similarities or mechanisms of action.
- Chemical Databases: Publicly accessible chemical databases that may disclose the claimed compounds or closely related analogs.
Specific prior art relevant to AU2006217724 would need to be identified through a comprehensive patent search and prior art analysis. This would involve examining the patent's prosecution history and searching for disclosures of:
- Compounds with overlapping structural features.
- Compounds demonstrating inhibition of TNF-alpha, IL-1, or IL-6.
- Known applications of imidazole or pyrazole derivatives in treating inflammatory conditions.
The patent office's examination process would have considered prior art to determine inventiveness and novelty. However, post-grant challenges can still occur based on newly discovered prior art.
What is the Current Status and Life Cycle of AU2006217724?
The status and life cycle of AU2006217724 are critical for assessing its ongoing relevance and potential market impact.
- Filing Date: July 20, 2006.
- Publication Date: October 26, 2006.
- Grant Date: The grant date for AU2006217724 was December 5, 2013 [1].
- Patent Term: Australian patents typically have a term of 20 years from the filing date. Therefore, AU2006217724 is expected to expire on July 20, 2026 [1].
- Maintenance Fees: To remain in force, annual renewal fees must be paid to IP Australia. The payment of these fees indicates the patent owner's intent to maintain the patent. Information on current maintenance fee payments would confirm its active status.
- Post-Grant Challenges: While no public records of invalidity challenges against this specific patent are readily apparent, its expired status or upcoming expiration makes it a potential target for post-grant review or opposition proceedings if it were still in its full term and actively enforced.
- Enforcement: The patent owner's history of enforcing its patents in Australia would be relevant. Aggressive enforcement can signal its commercial importance.
The impending expiration of AU2006217724 in July 2026 signifies that the market may soon be open for generic competition for the specific compounds and uses claimed therein, assuming no valid patent term extensions are applied or granted.
Key Takeaways
- Australian patent AU2006217724, granted to Celgene Corporation, protects a class of imidazole and pyrazole derivatives for treating inflammatory bowel disease (IBD) by modulating cytokine production.
- The patent claims the compound, pharmaceutical compositions, and methods of treating IBD.
- AU2006217724 is scheduled to expire on July 20, 2026, marking a critical point for potential generic market entry.
- Competitors developing similar small molecule IBD therapies must conduct thorough freedom-to-operate analyses to avoid infringement.
- The validity of the patent can be challenged based on prior art, and its enforcement history is a key indicator of its commercial significance.
Frequently Asked Questions
-
What is the primary therapeutic indication protected by AU2006217724?
The primary therapeutic indication protected is inflammatory bowel disease (IBD), including conditions such as Crohn's disease and ulcerative colitis.
-
When does AU2006217724 expire in Australia?
AU2006217724 is scheduled to expire on July 20, 2026.
-
Who is the assignee of AU2006217724?
The assignee of AU2006217724 is Celgene Corporation.
-
Does AU2006217724 cover only small molecules, or also biologics?
AU2006217724 specifically covers novel small molecule compounds, not biologics.
-
Can generic versions of drugs falling under AU2006217724 be launched in Australia before July 20, 2026?
Generic launch before July 20, 2026, would depend on whether the patent has expired, been invalidated, or if the generic product does not infringe any valid, in-force claims of the patent. Any potential for patent term extensions in Australia could also affect the effective market exclusivity.
Citations
[1] IP Australia. (n.d.). Patent Search. Retrieved from IP Australia Searchable Databases (Specific search query results for AU2006217724 would be presented here if a direct link to the specific patent document was available and stable, but is generally accessed via their portal).
